PAVmed (NASDAQ:PAVM – Get Free Report) is scheduled to issue its quarterly earnings data before the market opens on Thursday, November 14th. Analysts expect the company to announce earnings of ($1.30) per share for the quarter. Persons that wish to register for the company’s earnings conference call can do so using this link.
PAVmed (NASDAQ:PAVM – Get Free Report) last released its earnings results on Tuesday, August 13th. The company reported ($0.84) earnings per share (EPS) for the quarter. The business had revenue of $0.98 million during the quarter. On average, analysts expect PAVmed to post $-5 EPS for the current fiscal year and $-5 EPS for the next fiscal year.
PAVmed Price Performance
Shares of PAVM stock opened at $1.12 on Wednesday. PAVmed has a 12 month low of $0.60 and a 12 month high of $4.88. The firm has a market cap of $11.66 million, a PE ratio of -0.14 and a beta of 0.69. The stock has a 50 day moving average of $1.23 and a 200-day moving average of $1.20.
Wall Street Analyst Weigh In
Read Our Latest Report on PAVM
PAVmed Company Profile
PAVmed Inc focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck.
Featured Articles
- Five stocks we like better than PAVmed
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Home Depot Stock: Targeting 12% in 2024 and 25% More in 2025
- How to Calculate Options Profits
- Is Tesla’s Valuation a Bubble or Backed by Real Growth?
- Insider Buying Explained: What Investors Need to Know
- Trucking Stocks Led the Pack Last Week: Can They Keep Rolling?
Receive News & Ratings for PAVmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAVmed and related companies with MarketBeat.com's FREE daily email newsletter.